Edition:
United Kingdom

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

2.51USD
21 Feb 2018
Change (% chg)

$-0.08 (-3.09%)
Prev Close
$2.59
Open
$2.60
Day's High
$2.64
Day's Low
$2.50
Volume
123,911
Avg. Vol
190,101
52-wk High
$10.05
52-wk Low
$2.44

Chart for

About

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant... (more)

Overall

Beta: 2.03
Market Cap(Mil.): $187.67
Shares Outstanding(Mil.): 41.07
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Advaxis Announces Proposed Public Offering Of Common Stock

* ADVAXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

21 Feb 2018

BRIEF-Advaxis Expects To Report $59.4 Million Of Cash, Cash Equivalents And Investments As Of Jan 31

* ADVAXIS INC SAYS EXPECTS TO REPORT THAT IT HAD $59.4 MILLION OF CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JANUARY 31, 2018 - SEC FILING Source text: (http://bit.ly/2BHztlx) Further company coverage:

21 Feb 2018

BRIEF-Advaxis Submits Conditional MAA For Second-Line Metastatic Cervical Cancer Treatment In European Union

* ADVAXIS SUBMITS CONDITIONAL MARKETING AUTHORIZATION APPLICATION FOR AXALIMOGENE FILOLISBAC FOR THE SECOND-LINE TREATMENT OF METASTATIC CERVICAL CANCER IN EUROPEAN UNION

13 Feb 2018

BRIEF-Advaxis Says Expects Its Current Cash Position Will Be Sufficient To Fund Its Business Plan Into Fiscal 2019

* ADVAXIS REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

20 Dec 2017

BRIEF-Advaxis Q4 loss per share $1.74

* Advaxis reports business update and third quarter 2017 results

11 Sep 2017

Earnings vs. Estimates